Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prolexys begins clinical trials for cancer drug
The first Phase I study of the compound, PRLX 93936, will be a dose-escalating trial involving up to 36 patients. PRLX 93936 is a structural analog of a
The first Phase I study of the compound, PRLX 93936, will be a dose-escalating trial involving up to 36 patients. PRLX 93936 is a structural analog of a
Methylnaltrexone is a peripherally acting mu-opioid receptor antagonist that is designed to treat opioid-induced constipation (OIC) without interfering with pain relief. A new drug application for the subcutaneous
The agreement covers both an initial research collaboration and an option to Teva for a worldwide exclusive development and commercialization license. CGEN-54, a drug candidate for chronic inflammatory
ALS-357 is a novel drug entering Phase I/II clinical development that has demonstrated potent anti-tumor activity against malignant melanoma. Rapid tumor regression has been shown in a mouse
The double-blind, placebo-controlled trial will evaluate safety, tolerability and immune responses in up to 60 healthy volunteers aged 18 to 45 at two US clinical sites. According to
The companies believe the acquisition will create the US's premier provider of comprehensive diabetes care and treatment. “We will continue to invest strategically in capabilities supporting our therapeutic
The trial is being conducted at multiple sites in the European Union. Patients under the age of 60 with relapsed or refractory acute myeloid leukemia (AML), or patients
Each 1000mg injection of Nebido would only need to be provided once every 12 weeks, as compared to the current injectable therapies which typically require an injection every
DRC will also provide a $15 million milestone payment in 2012 should certain royalty recognition levels be met. Peg-Intron (peginterferon alpha-2b), is approved for the treatment of hepatitis
In the collaboration, Californian drug developer KineMed will identify new therapeutic utility in in vivo preclinical models by applying its proprietary translational medicine technologies. Once a disease target